IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 151-175 out of 1425.

<< < 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 > >>

Public Release: 7-Jul-2016
JAMA Oncology
Acupressure reduced fatigue in breast cancer survivors
Acupressure helped reduce persistent fatigue in women who had been treated for breast cancer, a new study finds.
National Institutes of Health

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System

Public Release: 7-Jul-2016
JCI Insight
Immune checkpoint blockade improves antitumor vaccine response in mouse glioblastoma model
In this issue of JCI Insight, Robert Prins of UCLA and colleagues tested whether they could improve the efficacy of an antitumor vaccine in a murine glioblastoma model by simultaneously administering therapeutic antibodies that turn off so-called immune checkpoint molecules, known as PD-1 and PD-L1, which attenuate immune responses.
National Institutes of Health, NIH/National Cancer Institute, Isabel Neidorf Foundation, Musella Foundation for Brain Tumor Research, UCLA Medical Scientist Training Program

Contact: Corinne Williams
press_releases@the-jci.org
JCI Journals

Public Release: 7-Jul-2016
JAMA Otolaryngology - Head & Neck Surgery
Combination chemo-radiation therapy may help preserve larynx for patients with laryngeal cancer
In a study published online by JAMA Otolaryngology-Head & Neck Surgery, James A. Bonner, M.D., of the University of Alabama at Birmingham, and colleagues assessed the rates of laryngeal (having to do with the larynx [voice box]) preservation and laryngectomy-free survival in patients receiving the monoclonal antibody cetuximab and radiation therapy (CRT) or radiation therapy alone.

Contact: Alicia Rohan
ARohan@uab.edu
205-975-7515
The JAMA Network Journals

Public Release: 7-Jul-2016
Cell
Cancer cell lines predict drug response
A discovery that cancer cell lines can be used to predict how a tumor is likely to respond to a drug has implications for developing new, personalized treatments.
Wellcome Trust, European Molecular Biology Laboratory, NIH/National Cancer Institute, Netherlands Organization for Scientific Research, EU/Seventh Framework Programme, La Fundació la Marató de TV3, European Research Council

Contact: Mary Todd Bergman
mary@ebi.ac.uk
44-788-137-7941
European Molecular Biology Laboratory - European Bioinformatics Institute

Public Release: 7-Jul-2016
Cell
A 'big data' approach to developing cancer drugs
Scientists are starting to accumulate huge datasets on which genes mutate during cancer, allowing for a more systematic approach to 'precision medicine.' In a study publishing July 7 in Cell, researchers compared genetic mutations in patient tumors to those in cancer cell lines and then tested the cell lines' responses to therapeutic compounds. By analyzing where these datasets overlap, researchers can begin to predict on a large scale which drugs will best fight various cancers.

Contact: Joseph Caputo
jcaputo@cell.com
617-397-2802
Cell Press

Public Release: 7-Jul-2016
New England Journal of Medicine
Two groundbreaking studies reflect new paradigm in breast cancer research
In a new paradigm of breast cancer research, physicians are fast-tracking promising new experimental drugs for further study, while immediately dropping drugs that don't work. Two such studies are published in the New England Journal of Medicine.

Contact: Jim Ritter
jritter@lumc.edu
708-216-2445
Loyola University Health System

Public Release: 7-Jul-2016
JCI Insight
Various miRNAs predict the effect of anti-angiogenic agents on renal cancer
CNIO researchers have come across various potential predictive biomarkers of tyrosine kinase inhibitors (TKI) -- a type of anti-angiogenic agent widely used -- response in metastatic renal cancer. In their study, published in JCI Insight, the researchers identify various miRNAs that define a group of patients with the poorest response to TKI treatment and with the worst prognosis. The study, conducted on 139 patient samples, is the most robust to date in renal cell carcinoma.
Mutua Madrileña Foundation, Pfizer, Fund for Health Research Project, Spanish Ministry of Economy, Competitiveness

Contact: Nuria Noriega
comunicacion@cnio.es
34-917-328-000
Centro Nacional de Investigaciones Oncológicas (CNIO)

Public Release: 7-Jul-2016
Cell
Cancer cell lines predict drug response and accelerate personalized medicine
Research published today in Cell has shown that patient-derived cancer cell lines harbor most of the same genetic changes found in patients' tumors, and could be used to learn how tumors are likely to respond to new drugs, increasing the success rate for developing new personalized cancer treatments.
Wellcome Trust, European Molecular Biology Laboratory, NIH/National Cancer Institute, Netherlands Organization for Scientific Research, EU/Seventh Framework Programme

Contact: Samantha Wynne
press.office@sanger.ac.uk
44-122-349-2368
Wellcome Trust Sanger Institute

Public Release: 7-Jul-2016
ESMO Open
Results of first study assessing clinical impact of ESMO-MCBS
Details of the first study by one of Europe's largest cancer centres, the Medical University of Vienna, assessing the clinical impact and feasibility of the ESMO Magnitude of Clinical Benefit Scale in a real-life context are now available on ESMO Open.

Contact: ESMO Press Office
media@esmo.org
European Society for Medical Oncology

Public Release: 7-Jul-2016
PLOS Biology
Mitochondria are exploited in cancer for tumor cell motility and metastatic competence
Scientists at The Wistar Institute have identified a specific network of proteins present in mitochondria of tumor cells that is essential for maintaining a clean function of mitochondria, enabling not only the proliferation of tumor cells but also their ability to move and invade distant organs. By understanding the players involved, Wistar scientists were able to turn off individual subunits within the network, which greatly reduced the ability of cancer cells to grow and spread, suggesting an attractive new therapeutic target.
National Institutes of Health, Italian Minister of Health, Prostate Cancer Research Program, Prostate Cancer Foundation

Contact: Ben Leach
bleach@wistar.org
215-495-6800
The Wistar Institute

Public Release: 7-Jul-2016
The EMBO Journal
The importance of keeping silent...in breast cancer cells
Researchers at the Centre for Genomic Regulation describe a repression mechanism active in hormone-dependent breast cancer cells for the first time. The repression complex of these cells silences genes related with cell proliferation and death, two key processes in cancer. The discovery contributes new knowledge on gene-silencing mechanisms and will help identify new targets for possible future treatments.

Contact: Laia Cendros
laia.cendros@crg.eu
34-607-611-798
Center for Genomic Regulation

Public Release: 7-Jul-2016
Nature
Loss of a microRNA family, let-7, found key in neuroblastoma
A study led by researchers at Dana-Farber/Boston Children's Cancer and Blood Disorders Center, finds that a microRNA called let-7 plays a central role in curbing neuroblastoma and could focus efforts to find a targeted, nontoxic alternative to chemotherapy.
National Institutes of Health, Alex's Lemonade Stand Foundation, Ellison Medical Foundation, Howard Hughes Medical Institute NIH/National Institute of General Medical Sciences

Contact: Keri Stedman
keri.stedman@childrens.harvard.edu
617-919-3110
Boston Children's Hospital

Public Release: 7-Jul-2016
Nature Cell Biology
Good indicator of cancer prognosis turned on its head by new research
A molecule which, for the last 20 years has been believed to be an indicator of good prognosis in tumors has been shown to have a dark side by new research from The Universities of Manchester, Athens and collaborators, recently published in Nature Cell Biology.

Contact: Jamie Brown
jamie.brown@manchester.ac.uk
44-161-275-8383
University of Manchester

Public Release: 7-Jul-2016
ecancermedicalscience
A step towards palliative care policy in Africa
ecancer's latest Special Issue provides an update on rapidly evolving developments in palliative cancer care in Africa.

Contact: Katie Foxall
katie@ecancer.org
01-174-033-093
ecancermedicalscience

Public Release: 6-Jul-2016
Genetics
'Omics' data improves breast cancer survival prediction
Precise predictions of whether a tumor is likely to spread would help clinicians and patients choose the best course of treatment. But current methods fall short of the precision needed. New research reveals that profiling primary tumor samples using genomic technologies can improve the accuracy of breast cancer survival predictions compared to clinical information alone. The study was published in the journal GENETICS, a publication of the Genetics Society of America.
National Institutes of Health, National Science Foundation, American Cancer Society, University of Alabama at Birmingham-Comprehensive Cancer Center

Contact: Cristy Gelling
cgelling@thegsajournals.org
412-478-3537
Genetics Society of America

Public Release: 6-Jul-2016
BJU International
Socioeconomic status influences the risk and stage of penile cancer
Low educational level, low disposable income, being divorced or never married, and living in a single-person household all increase the risk of advanced stage penile cancer, according to new research.

Contact: Penny Smith
sciencenewsroom@wiley.com
Wiley

Public Release: 6-Jul-2016
Future Oncology
Special issue of Future Oncology explores the field of Oncofertility
Future Science Group published journal, Future Oncology, has released a special issue that examines the field of oncofertility, which aims to preserve fertility in cancer patients.

Contact: Leela Ripton
l.ripton@future-science-group.com
44-208-371-6090
Future Science Group

Public Release: 6-Jul-2016
European Urology
Changes in benign tissue next to prostate tumors may predict biomedical recurrence
Changes in benign tissues next to prostate tumors may provide an early warning for patients at higher risk for biochemical recurrence after a radical prostatectomy, a study by researchers at Case Western Reserve University and Johns Hopkins Medical Institutions shows. If the preliminary findings are confirmed, the scientists recommend combining the benign-field features with tumor features extracted from patient's pathology images and Gleason scoring, to further improve the prediction of recurrence.
NIH/National Cancer Institute, NIH/National Institute of Diabetes and Digestive and Kidney Disease, DOD/Prostate Cancer Synergistic Idea Development Award, DOD/Lung Cancer Idea Development New Investigator Award, others

Contact: Kevin Mayhood
kevin.mayhood@case.edu
216-534-7183
Case Western Reserve University

Public Release: 6-Jul-2016
JAMA Dermatology
Many top selling sunscreens don't offer adequate protection
About 40 percent of top selling sunscreens on Amazon.com don't meet AAD guidelines, largely due to a lack of water resistance. The study also found consumers spend up to 3,000 percent more for products that provide the same sunscreen protection as lower-cost sunscreens. Dermatologists wanted to identify high performing products that are affordable and popular to know what to recommend to their patients and increase the likelihood of their using it.

Contact: Marla Paul
marla-paul@northwestern.edu
Northwestern University

Public Release: 6-Jul-2016
Annals of Surgical Oncology
Women trust their own instincts when choosing breast cancer surgery
A research team led by Breast Health Fellow Rebecca M. Kwait, M.D., at The Breast Health Center at Women & Infants Hospital of Rhode Island, a Care New England hospital, recently presented research indicating that when faced with a decision on the type of surgery to have to remove breast cancer, more women trust their own judgment over the input of their surgeon and even their partner.

Contact: Susan McDonald
slmcdonald@wihri.org
401-681-2816
Care New England

Public Release: 6-Jul-2016
Oncogene
Penn team finds mitochondrial stress induces cancer-related metabolic shifts
New findings from University of Pennsylvania researchers suggest that mitochondrial stress alone can trigger the metabolic shifts that accompany tumor growth, working through a pathway that involves p53, a protein widely known to play multiple important roles in cancer.
National Institutes of Health

Contact: Katherine Unger Baillie
kbaillie@upenn.edu
215-898-9194
University of Pennsylvania

Public Release: 6-Jul-2016
Cancer Discovery
Mass. General team finds how obesity contributes to, blocks treatment of pancreatic cancer
Massachusetts General Hospital investigators have discovered the mechanism by which obesity increases inflammation and desmoplasia -- an accumulation of connective tissue -- in the most common form of pancreatic cancer and also identify a treatment strategy that may inhibit the process.
National Institutes of Health, Lustgarten Foundation, Foundation for Science and Technology of Portugal

Contact: Katie Marquedant
kmarquedant@partners.org
617-726-0337
Massachusetts General Hospital

Public Release: 6-Jul-2016
Science Translational Medicine
New screening test using blood biomarkers may identify risk of colon cancer recurrence
Ludwig researchers working in collaboration with colleagues in Australia and the US have shown that fragments of tumor DNA circulating in the blood can be used to gauge the risk of colorectal cancer recurrence and the efficacy of chemotherapy following surgery. The finding, published today in the current issue of the journal Science Translational Medicine, is an important step toward the development of a non-invasive and more effective test for the detection, monitoring and treatment of cancer.
Ludwig Cancer Research, Conrad N. Hilton Foundation, Johns Hopkins/Sol Goldman Sequencing Facility, National Institutes of Health, Victorian Cancer Agency

Contact: Rachel Steinhardt
rsteinhardt@licr.org
Ludwig Institute for Cancer Research

Public Release: 6-Jul-2016
Annals of Oncology
ESMO releases new consensus guidelines on the management of metastatic colorectal cancer
ESMO, the leading European professional organisation for medical oncology, has released new consensus guidelines for the management of metastatic colorectal cancer that reflect an increasingly personalized approach to treatment, as published online today in Annals of Oncology

Contact: ESMO Press Office
media@esmo.org
European Society for Medical Oncology

Public Release: 6-Jul-2016
Scientific Reports
New microfluidic device offers means for studying electric field cancer therapy
A new MIT-designed microfluidic device with implantable electrodes slows tumor progression while leaving healthy cells intact.
National Research Foundation of Singapore through the Singapore-MIT Alliance for Research and Technology BioSystems and Micromechanics interdisciplinary research group

Contact: Sarah McDonnell
s_mcd@mit.edu
617-253-8923
Massachusetts Institute of Technology

Showing releases 151-175 out of 1425.

<< < 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 > >>

  Search News Releases

     

 

EurekAlert!